Skip to main content

Esbriet

Pronunciation: es-BREE-et
Generic name: pirfenidone
Dosage form: oral tablet, oral capsule
Drug class: Miscellaneous uncategorized agents

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 11, 2024.

What is Esbriet?

Esbriet ((pirfenidone) may be used to treat adults with idiopathic pulmonary fibrosis (IPF), a lung condition that causes inflammation and scarring in the lungs.

Esbriet’s mechanism of action involves slowing down the build-up of scar tissue in the lungs. The exact way it works for IPF is not known, but it does have anti-inflammatory, antioxidant, and anti-fibrotic properties. Esbriet is not a cure for IPF, but it does slow how quickly the condition progresses. Clinical studies have reported that Esbriet may prolong overall survival in patients with IPF by 2.5 to 5 years (see Does Esbriet improve survival?).

Esbriet gained FDA approval on October 15, 2014. An Esbriet generic is available under the name pirfenidone.

Esbriet cost

Esbriet is available as generic pirfenidone or as the brand Esbriet. With the Esbriet Copay Program, eligible patients with commercial insurance could pay as little as $5 per 30-day supply of Esbriet. See here for eligibility criteria.

For people with financial difficulty or who do not have insurance coverage, the Genentech Patient Foundation gives free Esbriet to eligible people (see here for criteria).

See Esbriet Prices, Coupons, Copay Cards & Patient Assistance for the cost of Esbriet capsules and tablets.

Esbriet side effects

The most common side effects of Esbriet are:

Serious side effects and warnings

Esbriet may cause the following serious side effects.

Liver problems. High liver enzymes and liver damage have occurred in people taking Esbriet. Call your doctor right away if you have unexplained symptoms such as yellowing of your skin or the white part of your eyes (jaundice), dark or brown (tea-colored) urine, pain on the upper right side of your stomach area (abdomen), bleeding or bruising more easily than normal, feeling tired.

Your doctor will do blood tests to check how your liver is working during your treatment with Esbriet.

Esbriet may make your skin more sensitive to sunlight and cause a rash. See “What should I avoid while taking Esbriet?”

Esbriet has caused severe skin reactions. Call your doctor right away if you have a severe skin reaction, such as skin blisters, rash, sores in the mouth, hives, or any other severe skin symptoms. Your doctor may stop your treatment with Esbriet.

Stomach problems, such as nausea, vomiting, diarrhea, indigestion, heartburn, and stomach pain have also been reported with Esbriet. Tell your doctor right away if your stomach problems get worse or do not go away.

Your doctor may need to change your dose of Esbriet if you develop any of these reactions.

It is not known if Esbriet is safe or effective in children.

These are not all the possible side effects of Esbriet. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Before taking

Before you take Esbriet, tell your doctor about all of your medical conditions, including if you:

Pregnancy

It is not known if Esbriet will harm your unborn baby.

Breastfeeding

It is not known if Esbriet passes into your breast milk. You and your doctor should decide if you will take Esbriet or breastfeed.

How should I take Esbriet?

Take Esbriet exactly as your doctor tells you to take it. Your doctor may change your dose of Esbriet as needed.

Your doctor should do certain blood tests before you start taking Esbriet.

Esbriet dosing information

The recommended dosage of Esbriet for adults with IPF is below. The maximum total daily dose of Esbriet is 2403 mg/day.

Treatment days Dosage Total daily dose
Days 1 through 7 267 mg 3 times a day 801 mg/day
Days 8 through 14 534 mg 3 times a day 1602 mg/day
Days 15 onwards 801 mg 3 times a day 2403 mg/day

What should I avoid while taking Esbriet?

Avoid sunlight. Esbriet can make your skin sensitive to the sun and the light from sunlamps and tanning beds.

Avoid smoking. Smoking may affect how well Esbriet works.

What happens if I miss a dose of Esbriet?

Take the missed dose as soon as you remember but if it is almost time for your next dose, miss that dose, and go back to your regular dosing schedule. Do not take 2 doses at the same time to make up for your missed dose.

If you miss 14 days or more of Esbriet call your doctor right away for further instructions about how to take your medicine.

What happens if I take too much Esbriet?

Do not take more than 3 doses of Esbriet each day. If you take too much Esbriet, call your doctor or go to the nearest hospital emergency room right away.

What other drugs will affect Esbriet?

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Moderate (such as ciprofloxacin) and strong inhibitors of CYP1A2 (such as fluvoxamine) increase blood levels of Esbriet and may increase the risk of side effects.  

Does Esbriet interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Esbriet storage

Store Esbriet capsules and tablets at room temperature, 77°F (25°C). Keep in a tightly closed container.

Safely throw away any Esbriet that is out of date or no longer needed. Keep Esbriet and all medicines out of reach of children

Esbriet ingredients

Active ingredient: pirfenidone

Inactive ingredients (Esbriet capsules): microcrystalline cellulose, croscarmellose sodium, povidone, and magnesium stearate. Capsule Shell: gelatin and titanium dioxide. Capsule Brown Printing Ink: shellac, iron oxide black, iron oxide red, iron oxide yellow, propylene glycol, ammonium hydroxide.

Inactive ingredients (Esbriet tablets): microcrystalline cellulose, colloidal anhydrous silica, povidone, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, macrogol (polyethylene glycol), talc, and iron oxide.

Available as Esbriet 267 mg capsules, Esbriet 267 mg tablets, and Esbriet 801 mg tablets.

Who makes Esbriet?

Genentech USA, Inc makes Esbriet.

Popular FAQ

How effective is Ofev for pulmonary fibrosis?

Results from three, 52-week long clinical studies in 1,231 people with idiopathic pulmonary fibrosis (IPF) showed that Ofev 150 mg orally twice daily significantly reduced the decline in the Forced Vital Capacity (FVC) by about 50% to 68% over 52 weeks when compared to a group of people not taking Ofev. FVC measures the amount of air which you can forcibly exhale from your lungs after taking the deepest breath possible. Continue reading

Does Esbriet improve survival?

Clinical studies have reported that Esbriet (pirfenidone) may prolong overall survival in patients with idiopathic pulmonary fibrosis (IPF) by 2.5 to 5 years when compared to patients receiving best supportive care or no antifibrotic treatment. Continue reading

How long can you take Esbriet for?

Esbriet is a maintenance medicine meant to be taken long-term for the treatment of idiopathic pulmonary fibrosis (IPF), a lung disease. If you have a serious side effect your healthcare provider may decide you need to reduce your dose or stop treatment permanently. Continue reading

Can Ofev and Esbriet be given together?

There has been one phase 4 trial that has investigated the combination of Ofev (nintedanib) and Esbriet (pirfenidone) for idiopathic pulmonary fibrosis (IPF) that showed a slightly increased risk of side effects with combination treatment, but the trial was not large enough to make a solid conclusion about increased/decreased effectiveness. Both Ofev and Esbriet slow IPF’s worsening but do not stop its progression, and neither medication is recommended over the other. Because they work on different aspects of the fibrotic cascade, there has been some suggestion that there may be some benefit in combining them. Continue reading

View more FAQ

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.